Skip to content

Study of Harishankara Rasa and its effect on Madhumeha(Type 2 Diabetes)

Pharmaceutical Study of Harishankara Rasa and Its Efficacy in the Management of Madhumeha (Type 2 Diabetes)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/03/018030
Enrollment
60
Registered
2019-03-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Harishankara Rasa with Nisha Amlaki: One group will be treated with 2 tablets of Harishankara Rasa with Nisha Amalaki (500mg) twice a day with luke warm water before meal (morning and e

Sponsors

IPGT and RA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients having chief & associated complains of Madhumeha(Prabhuta-Avilamutrata, pipashadhikya, kshudhadhikya etc) Patients having Fasting blood sugar level >= 126 mg/dl and or PPBS level >= 200 mg/dl Known patient of Type2 Diabetes and also the preliminarily diagnosed patients on the basis of signs and symptoms of the disease are confirmed by FBS and PPBS.

Exclusion criteria

Exclusion criteria: Age more than 60 and below 30 years Prameha pidaka (Diabetic nonhealing wound), Systemic infection, active infection other than superficial mild skin infestation Secondary Diabetes mellitus. Patients of any other severe illness. Diabetes mellitus Type 1 Malignant and accelerated hypertensive. Other chronic debilitating diseases. Pregnant woman and expecting conception (within six month) Lactating mothers. Patients with fatal diabetic complication like end stage renal disease Patient with diabetic ketoacidosis

Design outcomes

Primary

MeasureTime frame
Monitoring of persistence improvement in glycemic control by Harishankara Rasa after cessation of therapyTimepoint: At the End of Follow Up Period

Secondary

MeasureTime frame
Improves quality of life of patientsTimepoint: At the End of the Follow up Period

Countries

India

Contacts

Public ContactDr Prashant Bedarkar

IPGT and RA

drprashantbedarkar@gmail.com8128217370

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026